<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104048">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01715961</url>
  </required_header>
  <id_info>
    <org_study_id>CHB 11-02</org_study_id>
    <nct_id>NCT01715961</nct_id>
  </id_info>
  <brief_title>Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma</brief_title>
  <acronym>SARCOPENIE</acronym>
  <official_title>Multicentric Prospective Study to Assess the Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Henri Becquerel</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is a multicentric prospective study to assess the clinical and
      prognostic value of sarcopenia in patients older than 70 years with diffuse large B-cell
      lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sarcopenia status is assessed by CT scan imaging on the overall survival at 18 months in
      patients older than 70 years with diffuse large B-cell lymphoma treated by R-CHOP.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>at 18 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>at 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of over grade 2 toxicities</measure>
    <time_frame>at the first and second  courses of chemotherapy (day 21 and day 42)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determination of both molecular subtypes GCB and ABC</measure>
    <time_frame>at 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>according DASL technology (c-DNA mediated annealing selection extension and ligation)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Grade IIIB Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>anthropometric measurement</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The muscle area assessed by CT scan imaging at a lumbar vertebral landmark (L3) at the time of diagnosis, at the end of treatment, at 12 and 18 months
anthropometric measures (weight, height, BMI, brachial and calf circumference) and MNA (mini nutritional assessment)
albuminemia, transthyretin, orosomucoid, CRP
functional test to attest the muscular strength: hand grip test, unipodal test, up and go test
hematological and non-hematological chemotherapy toxicities of cycle 1 and cycle 2
OS and PFS at 18 and 24 months
GCB and ABC phenotypes determined by immunohistochemistry and transcriptome analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>anthropometric measurement</intervention_name>
    <description>To attest the muscular strength: hand grip test, balance test, up and go test</description>
    <arm_group_label>anthropometric measurement</arm_group_label>
    <other_name>Hand Grip strength test</other_name>
    <other_name>Timed get up and go test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;= 70 years

          -  DLBCL, grade IIIB follicular lymphoma or histologically proven transformed low grade
             lymphoma

          -  Whatever the IPI score and the performance status

          -  Treated by Rituximab-CHOP or  Rituximab-mini-CHOP

          -  CT scan imaging performed one month or less before inclusion

          -  Signed informed consent

        Exclusion Criteria:

          -  No initial CT scan imaging performed more than one month before inclusion

          -  Positivity for  HCV, HBV and HIV

          -  Anthracycline contra-indication
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice JARDIN, MD;PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Henri Becquerel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>April 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>70 years old</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Rituximab-CHOP</keyword>
  <keyword>Sarcopenia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
